On June 17th, GeLongHui reported that Chongqing Pharscin Pharmaceutical (002907.SZ) recently received the "Drug Registration Certificate" (Certificate No. 2024S01025, Certificate No. 2024S01026) issued by the National Medical Products Administration for the company's product Fumaric Acid Vinorelbine Tablets (10mg and 20mg) (hereinafter referred to as "the drug").
Fumaric Acid Vinorelbine Tablets are a second-class drug of the National Medical Insurance in the 2023 version. According to data from yaozh.com, the overall market share of Fumaric Acid Vinorelbine Tablets in 2023 is 439 million yuan. The drug is a potassium-competitive acid blocker (P-CAB) used to treat acid-related diseases, including reflux esophagitis (RE), gastric ulcers, duodenal ulcers, etc. Its mechanism of action is to block the K+ channel of H+/K+-ATP enzyme, competitively inhibit the binding between K+ and the enzyme, and stay in the gastric wall cells for a long time, thereby quickly inhibiting the secretion of gastric acid.